Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

ABSTRACT: Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).

DISEASE(S): Pancreatic Cancer Metastatic,Colon Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Pancreatic Neoplasms,Neoplasms

PROVIDER: 2370817 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR